Scarica l'app Stockscreener
2.84
0.71%
0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Gt Biopharma Inc Borsa (GTBP) Ultime notizie
GT Biopharma appoints David Mun-Gavin to board of directors By Investing.com - Investing.com India
GT Biopharma Appoints New Member To Its Board Of Directors - marketscreener.com
GT Biopharma (GTBP) Enhances Board with New Appointment | GTBP Stock News - GuruFocus
GT Biopharma Appoints New Member to its Board of Directors - GlobeNewswire
GT Biopharma Strengthens Board Before Critical Cancer Drug Results: Banking Expert Joins NK Cell Pioneer - Stock Titan
GTBP: GT Biopharma Plans Major Stock Sale | GTBP Stock News - GuruFocus
GT Biopharma registers 120.6M shares for resale by selling stockholders - MSN
GT Biopharma Amends Share Purchase Agreement - TipRanks
GT Biopharma Reports Improved Quarterly Losses - TipRanks
GT Biopharma Expands Convertible Preferred Stock Offering - TipRanks
The Escalator: Zealand Pharma, GT Biopharma, PointClickCare and more - Medical Marketing and Media
This Natural Killer Treatment Could Help Transform How Cancer is Treated - Baystreet.ca
GT Biopharma, Inc. - MENAFN.com
GT Biopharma advances to next trial phase for cancer therapy By Investing.com - Investing.com South Africa
Ellis Martin Report: Goliath Resources Limited (CVE:GOT) Continues to Provide High Grade Gold Discoveries at Surebet in British Columbia - ABN Newswire
Ellis Martin Report: GT Biopharma Inc's (NASDAQ:GTBP) Michael Breen: Targeting Cancer Cells with a Natural Killer Based Immunotherapy - ABN Newswire
Stocks In Play - Baystreet.ca
Stocks In Play: GT Biopharma, Inc. By Baystreet.ca - Investing.com Canada
Ellis Martin Report: Blue Lagoon Resources (CNSX:BLLG) Weeks Away from Gold Production at the Dome Mountain Project - ABN Newswire
GT Biopharma advances to next trial phase for cancer therapy - Investing.com Australia
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals - marketscreener.com
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 - GlobeNewswire
GT Biopharma Phase 1 Trial Reveals Early Success: Cancer Drug Shows Safety and Immune Activation - Stock Titan
EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results - Benzinga
GT Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GT Biopharma appoints new board member By Investing.com - Investing.com Nigeria
GT Biopharma (GTBP) Welcomes New Board Member Andrew Ritter | GTBP Stock News - GuruFocus
TSX Yet to Run out of Steam - The Globe and Mail
GT Biopharma appoints new board member - Investing.com
GT Biopharma Strengthens Board with Biotech Exit Expert Andrew Ritter: 3 Successful Company Sales - Stock Titan
GT Biopharma adds Hilary Kramer to Board of Directors By Investing.com - Investing.com South Africa
GT Biopharma (GTBP) Appoints Hilary Kramer to Board of Directors - GuruFocus
GT Biopharma adds Hilary Kramer to Board of Directors - Investing.com
$12B Portfolio Expert Hilary Kramer to Guide NK Cell Pioneer GT Biopharma's Clinical Expansion - Stock Titan
GT Biopharma (GTBP) Appoints Hilary Kramer to Board of Directors | GTBP Stock News - GuruFocus
GT Biopharma (GTBP) Projected to Post Earnings on Wednesday - Defense World
GT Biopharma Board Restructures with New Appointments - TipRanks
GT Biopharma announces private placement deal By Investing.com - Investing.com India
GT Biopharma announces private placement deal - Investing.com
GT Biopharma Secures $5.45M in Private Placement - TipRanks
Nanobodies Market to Reach US$ 2.27 Billion by 2031: Growth - openPR.com
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):